RHEINFELDEN, Switzerland, September 3rd 2018 – Tillotts Pharma AG (“Tillotts”) and the Zeria Group are pleased to announce and welcome Dr. Karima Boubekeur as the Group’s new Global Head of Innovation as per September 1st 2018. Karima will lead the research and development (R&D) as well as the business development and licensing (BD&L) functions.
She joins the Zeria Group from AstraZeneca where she was Vice President Emerging Portfolio and Search & Evaluation. Karima has more than 30 years’ experience in the pharmaceutical industry where she held several global leadership positions in R&D and Partnering with companies including Novartis and Roche. She has worked in Switzerland, Japan and Sweden.
Karima’s main responsibility as Global Head of Innovation will be to bring Tillotts and the Japanese parent company Zeria closer together to leverage both organisations’ expertise in R&D and BD&L. With this approach, the companies will be able to better focus and align the efforts towards developing a sustainable, well-balanced and innovative pipeline and portfolio of marketed products. The streamlining of processes and better utilisation of the existing expertise is a crucial step towards establishing a stronger and more sustainable business in indications with underlying inflammatory and fibrotic pathophysiology in the diseases of the digestive (GI) tract.
“I am delighted to join Tillotts and the Zeria Group and to be part of a growing team dedicated to improving the quality of life of patients suffering from GI-related diseases. I look forward to working alongside R&D leaders, talented employees, and partners to build on our core business, drive profitable growth and embrace operational excellence. Both companies are facing bright futures and I cannot wait to contribute to this journey,” Karima states.
CEO of Tillotts, Thomas A. Tóth von Kiskér adds, “With Karima, we have found the ideal top executive for the newly established role as Global Head of Innovation. She will play a crucial role in bringing the two companies to the next level by accelerating the creation of an innovative, global pipeline, with her extensive pharma expertise in both Europe and Japan. This is an extremely important position for Tillotts as we believe a key element of the company’s continued success is to move into closer collaboration not only with our Japanese parent company but also with other pharmaceutical companies as well as with universities and other academic research centres.”
Karima Boubekeur © Tillotts Pharma AG
To read the press release in German, click here
For more information, please contact Julie Delin Fosdal, Manager Corporate Communications:
Phone: +41 61 935 2761 | Email
Tillotts Pharma AG, part of the Japanese Zeria Group, is a fast-growing specialty pharma company with over 300 employees in Switzerland and abroad. Tillotts is dedicated to the development, in/out-licensing and commercialisation of innovative pharmaceutical products for the digestive system. Tillotts successfully markets its own products for the treatment of IBD as well as in-licensed products, in around 65 countries through its affiliates within Europe and a network of gastroenterology-focused partners throughout the world.
All trademarks used or mentioned here are protected by law. © Copyright Tillotts Pharma AG. All rights reserved.
Zeria Pharmaceutical Co., Ltd., founded in 1955, based in Tokyo, Japan, focuses on R&D, manufacturing and sales of prescription drugs as well as OTC products. The company is listed on the First Section of Tokyo Stock Exchange (Stock code: 4559). Zeria holds a leading position within the gastroenterology field in Japan and operates internationally through a number of subsidiaries. For more information about Zeria, please visit www.zeria.co.jp